Benzinga | Aug 25, 2020 07:42AM EDT

BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis Sept. 11-13

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the acceptance of a clinical abstract documenting an association between magnetic resonance imaging (MRI) measures and functional improvement in patients with progressive multiple sclerosis (MS). The data, to be presented as a poster on September 11-13 at the forthcoming MSVirtual2020 meeting -- the eighth joint meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) -- will inform analysis of clinical outcomes in the Company's ongoing Phase 2 trial of NurOwn(r) (MSC-NTF cells) in patients with progressive MS.